drugset / Trial / NCT04347473

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

NCT04347473

NaSingle-groupOpen-labelTreatment

Summary

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Timeline

Start
2020-04-06
Primary completion
2020-12-30
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tildrakizumab Monoclonal antibody 100 mg Subcutaneous

Indications